Atopic Dermatitis

Patients with atopic dermatitis who achieved rapid changes in skin pain severity with the Janus kinase inhibitor baricitinib were associated with clinically significant improvement in Dermatology Life Quality Index scores.

Only half of pediatric patients with atopic dermatitis who fit the criteria of having severe disease were identified as such by managing physicians.

Findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting showed that ruxolitinib cream (​​Opzelura) demonstrated significant improvement vs vehicle in patients with atopic dermatitis of Black race and across anatomic regions.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on considerations for dermatologists in seeking payer coverage of novel, expensive therapies for atopic dermatitis.

Sublingual immunotherapy with Dermatophagoides pteronyssinus extract was associated with significant improvements in disease severity among patients with atopic dermatitis sensitized to the house dust mite.

Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.

Longer-term findings of the Measure Up 1 and 2 studies showed the JAK inhibitor upadacitinib to be safe and effective after 52 weeks in the treatment of adults and adolescents with moderate to severe atopic dermatitis.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, discussed the psychosocial and behavioral issues faced by patients with atopic dermatitis, particularly those with severe disease.

Administering dupilumab for other atopic conditions, including atopic dermatitis (AD) and asthma, in patients who also have eosinophilic esophagitis (EoE), resulted in improved EoE symptoms.

Dupilumab was shown to significantly improve factors of skin barrier function, including transepidermal water loss, lipid composition, and filaggrin, among patients with moderate to severe atopic dermatitis.

Patients with severe atopic dermatitis showed significant associations with concomitant contact dermatitis and immune dysfunction after undergoing a multidisciplinary evaluation between allergy, immunology, and dermatology specialists.

Uncontrolled disease burden was a major unmet need among children with moderate to severe atopic dermatitis (AD) who were unresponsive to topical therapies.

Polish patients with atopic dermatitis reported lower overall health and impaired quality of life related to mental health in the first year of the COVID-19 pandemic.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the efficacy of biologics in the treatment of atopic dermatitis and other recently approved therapeutics.

Robert Sidbury, MD, MPH, chief of the Division of Dermatology at Seattle Children's Hospital, discusses risk factors involved in the pathogenesis of atopic dermatitis and several diagnostic methods.

Japanese children of parents whose family business was primarily industry, including agriculture, forestry, and fisheries, had a greater risk of atopic dermatitis (AD) development.

Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.

The JAK1 inhibitor abrocitinib (Cibinqo) was recently approved by the FDA for the treatment of adults with refractory, moderate to severe atopic dermatitis.

Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.

Researchers review current knowledge on the management of flares in atopic dermatitis, including treatment and unmet needs.

Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.

Patients with atopic dermatitis were associated with significant economic burden primarily driven by outpatient visits and pharmacy use, which increased with disease severity.

Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.

Patients with atopic dermatitis were shown to be more likely to receive a COVID-19 diagnosis than the general population.

Children and adolescents with atopic dermatitis (AD) tended to have a higher number of delinquent behaviors than those without AD, including fighting, cheating on exams, and suspension.

Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.

A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.